Clinical Trials Directory

Trials / Sponsors / Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited

Industry · 14 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Phelan-McDermid Syndrome
Phase 32025-11-12
WithdrawnAn Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Prader-Willi Syndrome
Phase 22023-09-01
CompletedAn Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Pitt Hopkins Syndrome
Phase 22022-10-14
CompletedAn Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
Phelan-McDermid Syndrome
Phase 22022-08-08
CompletedAn Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Angelman Syndrome
Phase 22022-07-12
CompletedTo Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
Healthy Volunteers
Phase 12020-05-29
CompletedA Safety Study of NNZ-2566 in Pediatric Rett Syndrome
Rett Syndrome
Phase 22016-03-01
TerminatedA Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
Concussion
Phase 22014-09-01
CompletedA Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Fragile X Syndrome
Phase 22014-01-01
CompletedA Safety Study of NNZ-2566 in Patients With Rett Syndrome
Rett Syndrome
Phase 22013-03-01
CompletedStudy of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
Brain Injuries
Phase 22013-02-01
CompletedSafety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration
Brain Injuries, Traumatic
Phase 12012-02-01
CompletedStudy of NNZ-2566 in Patients With Traumatic Brain Injury
Brain Injuries
Phase 22010-04-01
CompletedSafety Study of NNZ-2566 in Healthy Female Subjects
Brain Injuries, Traumatic
Phase 12010-03-01